Dr. Prakash Peddi, MD

Dr. Peddi practices at WK Hematology Oncology Associates in Shreveport, Louisiana.

Dr. Peddi's NPI, 1093926446, was assigned on May 25, 2007. Dr. Peddi graduated from Brody School Of Medicine At East Carolina University in 2004. Dr. Peddi holds Louisiana license 203753.

Dr. Peddi's primary practice is WK Hematology Oncology Associates, at 2600 Kings Hwy, Shreveport, LA 71103 in Caddo Parish. The practice phone is (318) 212-8620.

Dr. Peddi's primary practice is WK Hematology Oncology Associates in Shreveport, Louisiana. Dr. Peddi is also affiliated with Willis Knighton North. The medical group on file is LSU Health Shreveport. Dmand AI also links Dr. Peddi to 2 more group practices and clinics, 1 home health agency and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Peddi practices, 4 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Peddi's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Peddi is licensed in Louisiana.

Dmand AI lists breast cancer, chronic anemia, chronic leukemia, colorectal cancer, deep vein thrombosis (DVT), lung cancer, lymphoma and neutropenia among the conditions Dr. Peddi treats.

CMS data shows 1,471 Medicare services from Dr. Peddi across 7 procedure codes in 2024, for 502 Medicare patients. Medicare paid $100,235 for them.

CMS counts 502 Medicare patients who saw Dr. Peddi in 2024. The largest group is 65 to 74, with 244 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 10% are also on Medicaid. Their average risk score is 1.52, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Peddi's median patient age at 70, with 80% women.

In 2024, Dr. Peddi wrote 3,030 Medicare Part D claims for 413 patients. 86% of them were for generic drugs. CMS names the drug for 2,796 of them, across 41 drugs with 11 or more claims each, at $3,868,879 in total drug cost. In 2023, CMS named 2,536 claims across 40 drugs.

Dr. Peddi accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 31 papers to Dr. Peddi, published from 2010 to 2025. 2017 was the busiest year, with 7. The most frequent topics are Breast Neoplasms, Diagnosis, Differential and Adenocarcinoma. Dr. Peddi has published most often in BMJ Case Rep. Dr. Peddi's most frequent co-authors are Quyen Dinh Chu, MD, Nebu V. Koshy, MD and Glenn Morris Mills, MD.

Dmand AI links Dr. Peddi to 3 clinical trials. Conditions studied include Breast Neoplasms, Triple Negative Breast Neoplasms and Brain Neoplasms. Open Payments lists research payments to Dr. Peddi that name 1 trial.

CMS Open Payments shows 1,505 general payments to Dr. Peddi from 73 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 75% of the total. AstraZeneca Pharmaceuticals LP paid the most, $111,599. It also lists 1 research payment totaling $1,024 in 2020, naming 1 clinical trial.

Dmand AI lists 1 award for Dr. Peddi, most recently Healer Award in 2016.

Dr. Peddi graduated from Brody School Of Medicine At East Carolina University in 2004.

Dr. Peddi is in network with 15 carriers, including Elevance, Aetna and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.